Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Wilson Therapeutics AB

Headquarters: Stockholm, Sweden
Website: N/A
Year Founded: 2012
Status: Acquired

BioCentury | Oct 29, 2024
Deals

Novartis adds another degrader, this time from Monte Rosa

Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Apr 27, 2023
Product Development

April 27 Quick Takes: AbbVie exits CF based on triplet’s readout

Plus: AZ cuts late-stage GLP-1, Wilson’s disease programs and updates from Sanofi, 4D Molecular, Generate
BioCentury | Mar 1, 2023
Management Tracks

C4’s Adam Crystal to head R&D at Tango

Plus: new CFO at BioArctic and updates from Sutro, Korro, BioAtla, Claris, Akoya and more
BioCentury | Nov 16, 2022
Management Tracks

Bungay becomes CEO at Imophoron, Garzoni transitions to CSO

Plus: Tracy named CTO at Code, and updates from ConcertAI, Lucy, Trevi and more
BioCentury | Dec 21, 2021
Product Development

Dec. 20 Quick Takes: Merck KGaA acquires neurology company Chord 

Plus: Novavax gets EU nod, Moderna, Cytokinetics, Amgen and more
BioCentury | Aug 27, 2021
Deals

Aug. 26 Quick Takes: Bolt, Innovent partner on non-traditional antibody conjugates

Plus ADC royalty deal, Sobi, Servier, DiCE IPO plans, AZ in Wilson’s and more
BioCentury | Oct 13, 2020
Finance

Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders

Omega Funds is sole investor for Swiss start-up’s series A, reuniting firm with CEO Plitz 
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

A rare Alexion deal for a marketed product comes at a relative discount as Portola’s stock price has sunk
Items per page:
1 - 10 of 43